company background image
S1GE34

Seagen BOVESPA:S1GE34 Stock Report

Last Price

R$34.86

Market Cap

R$131.5b

7D

0%

1Y

n/a

Updated

05 Feb, 2023

Data

Company Financials +

S1GE34 Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

S1GE34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$34.86
52 Week HighUS$48.36
52 Week LowUS$27.38
Beta0.57
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-40.69%

Recent News & Updates

Recent updates

Shareholder Returns

S1GE34BR BiotechsBR Market
7D0%-0.1%-2.9%
1Yn/a2.4%-15.4%

Return vs Industry: Insufficient data to determine how S1GE34 performed against the BR Biotechs industry.

Return vs Market: Insufficient data to determine how S1GE34 performed against the BR Market.

Price Volatility

Is S1GE34's price volatile compared to industry and market?
S1GE34 volatility
S1GE34 Average Weekly Movementn/a
Biotechs Industry Average Movement9.7%
Market Average Movement6.5%
10% most volatile stocks in BR Market10.4%
10% least volatile stocks in BR Market3.1%

Stable Share Price: Insufficient data to determine S1GE34's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine S1GE34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,675David Epsteinhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
S1GE34 fundamental statistics
Market CapR$131.53b
Earnings (TTM)-R$3.27b
Revenue (TTM)R$9.57b

13.7x

P/S Ratio

-40.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
S1GE34 income statement (TTM)
RevenueUS$1.86b
Cost of RevenueUS$1.68b
Gross ProfitUS$184.76m
Other ExpensesUS$821.53m
Earnings-US$636.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 15, 2023

Earnings per share (EPS)-3.43
Gross Margin9.91%
Net Profit Margin-34.16%
Debt/Equity Ratio0%

How did S1GE34 perform over the long term?

See historical performance and comparison